|
Individual response
|
|
121
|
14255
|
August 19, 2022
|
|
Patient-specific treatment effects in RCTs: why should one present them?
|
|
1
|
107
|
August 13, 2022
|
|
Language for communicating frequentist results about treatment effects
|
|
195
|
82607
|
August 6, 2022
|
|
What is a fake measurement tool and how are they used in RCT
|
|
45
|
10203
|
August 3, 2022
|
|
Analyzing compositional outcome data
|
|
5
|
831
|
July 28, 2022
|
|
Which to make as the primary analysis
|
|
1
|
421
|
July 25, 2022
|
|
Non-inferiority and choice of scale (absolute vs relative)
|
|
4
|
771
|
July 23, 2022
|
|
RCT with missing follow-up outcomes: ANCOVA + MI vs Mixed-Effects Modelling?
|
|
6
|
812
|
July 8, 2022
|
|
Evidence Based Decision Making and Meta-Analysis -- An Information Theoretic Critique
|
|
1
|
1499
|
June 10, 2022
|
|
Logistics of treatment effect estimation with interim analyses
|
|
1
|
477
|
June 1, 2022
|
|
Should adverse effects be adjusted for multiple comparisons?
|
|
4
|
1050
|
May 24, 2022
|
|
Quality of remdesivir trials
|
|
51
|
12239
|
May 12, 2022
|
|
Background to PFS endpoint
|
|
16
|
1647
|
May 8, 2022
|
|
Summary Statistics vs Raw Data
|
|
8
|
4654
|
May 7, 2022
|
|
Methodology: Benefit Risk Assessment when Risk and Benefit are only observed in different timing
|
|
5
|
755
|
April 18, 2022
|
|
Covariate adjustment in non-inferiority trials
|
|
3
|
760
|
April 14, 2022
|
|
RCT and "Mathematical Embellishment"
|
|
2
|
1101
|
April 5, 2022
|
|
Chi-Squared for relative risk
|
|
1
|
672
|
March 27, 2022
|
|
Analysis of 2x2 trial with anticipated treatment interaction
|
|
9
|
2312
|
March 25, 2022
|
|
How to calculate number of events in each treatment arm given hazard ratio and CI?
|
|
2
|
952
|
March 6, 2022
|
|
Covariate imbalance in RCT
|
|
5
|
1212
|
February 23, 2022
|
|
Estimate treatment effect in study with a composite complication score as outcome
|
|
9
|
1592
|
February 18, 2022
|
|
Single cluster cluster randomized crossover (CRXO) design?
|
|
3
|
968
|
February 17, 2022
|
|
Bernoulli trials vs completely randomized trials
|
|
0
|
1040
|
January 5, 2022
|
|
Catastrophic Heterogeneity Meets "The Clairvoyant RCT"
|
|
0
|
1167
|
December 28, 2021
|
|
Cost-effectiveness based interim analysis
|
|
2
|
1066
|
December 15, 2021
|
|
Interpretation of the REGEN-COV trial
|
|
22
|
4332
|
November 1, 2021
|
|
First RCT of Lopinavir–Ritonavir on SARS-CoV2
|
|
38
|
13779
|
October 8, 2021
|
|
Extensions of 'worst-rank' score methods with outcomes truncated by death
|
|
13
|
2152
|
September 2, 2021
|
|
Resources for Mixed-Effect Models in Medical Contexts
|
|
7
|
2205
|
August 8, 2021
|